文献速递脑血管病

卒中病因对急性基底动脉闭塞血管内治疗效果的影响:ATTENTION随机试验的事后分析

Effect of Stroke Etiology on Endovascular Treatment for Acute Basilar-Artery Occlusion: A Post Hoc Analysis of the ATTENTION Randomized Trial.
PubMed 文献 · Stroke · 2024-07-22

该研究为ATTENTION试验的事后分析,纳入340例急性基底动脉闭塞患者,按病因分为大动脉粥样硬化、心源性栓塞和不明原因/其他明确原因三组。比较最佳药物治疗联合血管内治疗与单纯最佳药物治疗,结果显示血管内治疗可能与大动脉粥样硬化及不明原因/其他明确原因组90天良好预后相关,心源性栓塞组未达统计学显著,病因与治疗交互作用P=0.89。

要点

  • 急性基底动脉闭塞患者中,血管内治疗在三种病因亚组均可能降低90天死亡率。
  • 大动脉粥样硬化组联合治疗90天良好预后率49.1% vs 单纯药物23.8%(OR 3.08,95%CI 1.38-6.89)。
  • 心源性栓塞组联合治疗90天良好预后率52.2% vs 单纯药物30.8%(OR 2.45,95%CI 0.89-6.77),未达统计学显著。

核心结论

  • 在急性基底动脉闭塞患者中,与单纯最佳药物治疗相比,血管内治疗可能与大动脉粥样硬化、心源性栓塞及不明原因/其他明确原因三种病因患者90天良好预后相关,并降低90天死亡率。
  • 卒中病因对血管内治疗获益的影响需进一步试验探索。

研究设计与样本

  • ATTENTION试验的事后分析,该试验为在中国36个中心开展的多中心随机试验,时间范围为2021年2月至2022年9月。
  • 共纳入340例急性基底动脉闭塞患者,按卒中病因分为大动脉粥样硬化组150例(44.1%)、心源性栓塞组72例(21.2%)、不明原因/其他明确原因组118例(34.7%)。
  • 比较最佳药物治疗联合血管内治疗与单纯最佳药物治疗在不同病因亚组中的疗效与安全性。

主要发现

  • 大动脉粥样硬化组联合治疗与单纯药物治疗的90天良好预后率分别为49.1%和23.8%(OR 3.08,95%CI 1.38-6.89)。
  • 心源性栓塞组联合治疗与单纯药物治疗的90天良好预后率分别为52.2%和30.8%(OR 2.45,95%CI 0.89-6.77)。
  • 不明原因/其他明确原因组联合治疗与单纯药物治疗的90天良好预后率分别为37.5%和17.4%(OR 2.85,95%CI 1.16-7.01)。
  • 卒中病因与治疗的交互作用P=0.89。
  • 血管内治疗患者中大动脉粥样硬化、心源性栓塞和不明原因/其他明确原因组症状性颅内出血发生率分别为8.3%、2.2%和3.2%,单纯药物治疗患者均无。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stroke etiology could influence the outcomes in patients with basilar-artery occlusion (BAO). This study aimed to evaluate the differences in efficacy and safety of best medical treatment (BMT) plus endovascular treatment (EVT) versus BMT alone in acute BAO across different stroke etiologies. METHODS: The study was a post hoc analysis of the ATTENTION trial (Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion), which was a multicenter, randomized trial at 36 centers in China from February 2021 to September 2022. Patients with acute BAO were classified into 3 groups according to stroke etiology (large-artery atherosclerosis [LAA], cardioembolism, and undetermined cause/other determined cause [UC/ODC]). The primary outcome was a favorable outcome (modified Rankin Scale score of 0-3) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage and 90-day mortality. RESULTS: A total of 340 patients with BAO were included, 150 (44.1%) had LAA, 72 (21.2%) had cardioembolism, and 118 (34.7%) had UC/ODC. For patients treated with BMT plus EVT and BMT alone, respectively, the rate of favorable outcome at 90 days was 49.1% and 23.8% in the LAA group (odds ratio, 3.08 [95% CI, 1.38-6.89]); 52.2% and 30.8% in the cardioembolism group (odds ratio, 2.45 [95% CI, 0.89-6.77]); and 37.5% and 17.4% in the UC/ODC group (odds ratio, 2.85 [95% CI, 1.16-7.01]), with P=0.89 for the stroke etiology×treatment interaction. The rate of symptomatic intracranial hemorrhage in EVT-treated patients with LAA, cardioembolism, and UC/ODC was 8.3%, 2.2%, and 3.2%, respectively, and none of the BMT-treated patients. Lower 90-day mortality was observed in patients with EVT compared with BMT alone across 3 etiology groups. CONCLUSIONS: Among patients with acute BAO, EVT compared with BMT alone might be associated with favorable outcomes and lower 90-day mortality, regardless of cardioembolism, LAA, or UC/ODC etiologies. The influence of stroke etiology on the benefit of EVT should be explored by further trials. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04751708.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yuan G, Nguyen TN, Liu L, et al. Effect of Stroke Etiology on Endovascular Treatment for Acute Basilar-Artery Occlusion: A Post Hoc Analysis of the ATTENTION Randomized Trial. Stroke. 2024. PMID: 39038096. doi:10.1161/STROKEAHA.124.047568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。